Whalesbook
Ajanta Pharma Secures Strategic Global Deal for Semaglutide Marketing
Ajanta Pharma has announced a significant in-licensing agreement with Biocon Limited, a move that PL Capital, a brokerage firm, views as a strong catalyst for future growth. PL Capital has maintained its 'Buy' rating on Ajanta Pharma shares, setting an optimistic target price of ₹3,200 per share. This partnership focuses on commercializing semaglutide, a key medication, across 26 emerging markets, a strategy analysts believe aligns perfectly with Ajanta Pharma's existing pharmaceutical franchise.
The Core Issue
The crux of the news lies in the strategic in-licensing agreement between Ajanta Pharma and Biocon. Under this arrangement, Biocon will serve as the manufacturing and supply partner for semaglutide. Ajanta Pharma, in turn, will lead the commercialization efforts, securing exclusive marketing rights in 23 of the covered markets and semi-exclusive rights in the remaining three. These territories span across Africa, the Middle East, and Central Asia, regions where Ajanta Pharma already possesses a substantial presence and distribution network.
Financial Implications
PL Capital forecasts robust financial performance for Ajanta Pharma stemming from this deal. The brokerage projects a compound annual growth rate (CAGR) of 17 percent for Ebitda and 14 percent for Profit After Tax (PAT) between Fiscal Year 2025 and 2028. Furthermore, Ajanta Pharma is expected to achieve healthy return on equity (RoE) of 28.1 percent and return on capital employed (RoCE) of 35.5 percent by Fiscal Year 2027. These projections underscore the financial upside anticipated from the semaglutide venture.
Market Opportunity and Projections
The addressable market for semaglutide across these 26 countries, currently estimated at $35 to $45 million (innovator-led), is poised for exponential expansion. With the anticipated entry of generic versions following patent expiries, projected around March 2026 in most territories, the market is expected to grow tenfold to twentyfold over the next two to three years. Ajanta Pharma is strategically positioned to capitalize on this growth. PL Capital estimates that Ajanta Pharma could generate sales of approximately ₹200 crore from its semaglutide franchise in these Rest of World (RoW) markets by Fiscal Year 2028, accompanied by healthy profit margins.
Ajanta Pharma's Branded Generics Strength
Ajanta Pharma's established branded generics (BGx) business forms a strong foundation for this new venture. This segment currently boasts a healthy operating profit margin (OPM) of 30 percent and contributed a significant 74 percent to the company's overall revenue in FY25. The BGx business has demonstrated consistent growth, with a revenue CAGR of 12.5 percent from FY22 to FY25, fueled by an expanding medical representative (MR) force and strategic market penetration. PL Capital anticipates this momentum to continue, projecting a 13-14 percent revenue CAGR for the BGx business from FY25 to FY28, driven by new product launches, geographic expansion, and increased MR productivity.
New Therapies and Future Outlook
Beyond the semaglutide deal, Ajanta Pharma is actively expanding its therapeutic offerings. In FY25, the company entered the nephrology and gynecology segments within the domestic Indian market, which represent a substantial ₹16,000 crore opportunity. The addition of 200 MRs and the launch of 12 products in these segments highlight the company's commitment to diversified growth. With a strong product pipeline across its key segments and the introduction of newer therapies, Ajanta Pharma appears well-positioned for sustained growth and market leadership.
Impact
This strategic partnership with Biocon is expected to significantly boost Ajanta Pharma's revenue streams and profitability, particularly in emerging markets. The company's ability to leverage its existing strong franchise for semaglutide commercialization, coupled with the projected market expansion, positions it for substantial market share gains. Investors may see this deal as a positive indicator of Ajanta Pharma's forward-looking strategy and its potential for significant returns, as reflected in the 'Buy' rating and target price from PL Capital. The stock could experience increased investor interest.
Difficult Terms Explained
- Ebitda: Earnings Before Interest, Tax, Depreciation, and Amortization. This is a measure of a company's operating performance before accounting for financing costs, taxes, and non-cash expenses like depreciation.
- PAT: Profit After Tax. This is the net profit remaining after all expenses, including taxes, have been deducted from the revenue.
- CAGR: Compound Annual Growth Rate. A measure of investment growth over a specified period, assuming profits are reinvested at the end of each year.
- RoE: Return on Equity. A profitability ratio that measures how effectively a company uses shareholder investments to generate profits.
- RoCE: Return on Capital Employed. A profitability ratio that measures how efficiently a company uses its capital to generate profits.
- In-licensing: A legal agreement where a company obtains the rights to use another company's intellectual property (like a drug formula) for specific purposes, such as marketing and selling in certain regions.
- Commercialization: The process of bringing a new product or service to the market and making it available for purchase by customers.
- Branded Generics (BGx): Generic drugs that are marketed and sold under a company's own brand name, rather than just the generic drug's name.
- Operating Profit Margin (OPM): A profitability ratio that shows how much profit is generated from sales after deducting operating expenses but before deducting interest and taxes.